Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Up 1.9% – Time to Buy?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)’s share price traded up 1.9% on Friday . The company traded as high as $23.80 and last traded at $23.61. 316,473 shares were traded during trading, a decline of 70% from the average session volume of 1,041,931 shares. The stock had previously closed at $23.16.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Finally, Bank of America reaffirmed a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus target price of $32.29.

Catalyst Pharmaceuticals Trading Up 4.6 %

The business’s 50-day simple moving average is $22.39 and its two-hundred day simple moving average is $21.62. The company has a market capitalization of $2.94 billion, a PE ratio of 20.53, a PEG ratio of 3.31 and a beta of 0.84.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth about $27,000. Park Square Financial Group LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth about $29,000. Farther Finance Advisors LLC raised its stake in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,495 shares during the period. Larson Financial Group LLC raised its stake in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth about $65,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.